Edgar Lomax Company’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.7M | Buy |
489,420
+424,210
| +651% | +$24.7M | 2.12% | 17 |
|
|
2025
Q4 | $3.52M | Sell |
65,210
-1,540
| -2% | -$74.1K | 0.27% | 55 |
|
|
2025
Q3 | $3.01M | Sell |
66,750
-19,840
| -23% | -$927K | 0.24% | 51 |
|
|
2025
Q2 | $4.01M | Sell |
86,590
-1,370
| -2% | -$67.3K | 0.25% | 51 |
|
|
2025
Q1 | $5.36M | Sell |
87,960
-107,640
| -55% | -$6.27M | 0.34% | 45 |
|
|
2024
Q4 | $11.1M | Sell |
195,600
-3,790
| -2% | -$212K | 0.71% | 48 |
|
|
2024
Q3 | $10.3M | Sell |
199,390
-3,175
| -2% | -$149K | 0.63% | 51 |
|
|
2024
Q2 | $8.41M | Sell |
202,565
-2,630
| -1% | -$118K | 0.55% | 52 |
|
|
2024
Q1 | $11.1M | Buy |
205,195
+88,933
| +76% | +$4.53M | 0.69% | 48 |
|
|
2023
Q4 | $5.97M | Sell |
116,262
-5,285
| -4% | -$277K | 0.39% | 48 |
|
|
2023
Q3 | $7.05M | Sell |
121,547
-4,475
| -4% | -$274K | 0.48% | 46 |
|
|
2023
Q2 | $8.06M | Sell |
126,022
-1,743
| -1% | -$117K | 0.53% | 44 |
|
|
2023
Q1 | $8.86M | Sell |
127,765
-25,750
| -17% | -$1.82M | 0.57% | 43 |
|
|
2022
Q4 | $11M | Sell |
153,515
-845
| -0.5% | -$63.7K | 0.67% | 44 |
|
|
2022
Q3 | $11M | Sell |
154,360
-1,600
| -1% | -$116K | 0.76% | 42 |
|
|
2022
Q2 | $12M | Buy |
155,960
+4,260
| +3% | +$324K | 0.75% | 40 |
|
|
2022
Q1 | $11.1M | Buy |
151,700
+1,650
| +1% | +$111K | 0.65% | 42 |
|
|
2021
Q4 | $9.36M | Sell |
150,050
-1,515
| -1% | -$88.9K | 0.56% | 48 |
|
|
2021
Q3 | $8.97M | Sell |
151,565
-2,950
| -2% | -$194K | 0.58% | 49 |
|
|
2021
Q2 | $10.3M | Sell |
154,515
-5,875
| -4% | -$383K | 0.64% | 49 |
|
|
2021
Q1 | $10.1M | Sell |
160,390
-17,355
| -10% | -$1.08M | 0.63% | 48 |
|
|
2020
Q4 | $11M | Sell |
177,745
-3,100
| -2% | -$191K | 0.75% | 41 |
|
|
2020
Q3 | $10.9M | Buy |
180,845
+7,400
| +4% | +$445K | 0.84% | 39 |
|
|
2020
Q2 | $10.2M | Buy |
173,445
+3,445
| +2% | +$206K | 0.82% | 40 |
|
|
2020
Q1 | $9.48M | Buy |
+170,000
| New | +$10.4M | 0.84% | 37 |
|
|
2014
Q4 | – | Sell |
-129,613
| Closed | -$6.63M | – | 71 |
|
|
2014
Q3 | $6.63M | Buy |
129,613
+3,300
| +3% | +$165K | 0.45% | 47 |
|
|
2014
Q2 | $6.13M | Buy |
126,313
+400
| +0.3% | +$19.7K | 0.43% | 49 |
|
|
2014
Q1 | $6.54M | Buy |
125,913
+21,750
| +21% | +$1.16M | 0.48% | 47 |
|
|
2013
Q4 | $5.54M | Sell |
104,163
-56,200
| -35% | -$2.86M | 0.42% | 53 |
|
|
2013
Q3 | $7.42M | Sell |
160,363
-14,700
| -8% | -$645K | 0.61% | 48 |
|
|
2013
Q2 | $7.82M | Buy |
+175,063
| New | +$7.6M | 0.61% | 48 |
|
Other funds holding BMY
VCM
VPM
Edgar Lomax Company's BMY Position: Q1 2026 in Review
Edgar Lomax Company increased its Bristol-Myers Squibb (BMY) stake by 651% in Q1 2026, buying an estimated $24.7M and bringing the position to 489,420 shares worth $29.7M. The position accounts for 2.12% of the portfolio, ranked #17.
Edgar Lomax Company first reported a position in BMY in Q2 2013 and has held it in 31 quarters since. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Edgar Lomax Company held 489,420 shares of Bristol-Myers Squibb worth $29.7M as of Q1 2026.
- Edgar Lomax Company bought 424,210 Bristol-Myers Squibb shares in Q1 2026, an estimated $24.7M.
- Bristol-Myers Squibb made up 2.12% of Edgar Lomax Company's portfolio in Q1 2026, its #17 holding.
- Edgar Lomax Company first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 31 quarters since.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Edgar Lomax Company's 13F filing for Q1 2026, filed 12 May 2026.